Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The high rate of grade 3 diarrhea seen in the Zanidatamab trial was likely exacerbated by the capecitabine-based chemotherapy common in the global study. US oncologists, who often prefer a Folfox regimen, may see less severe GI toxicity, potentially improving patient tolerance and adherence to this highly effective regimen.
Related Insights
Clinical trials with zanidatumab revealed significant diarrhea primarily in the first cycle. The successful management strategy involves mandatory loperamide twice daily for the first seven days to improve tolerability and prevent treatment discontinuation, a crucial implementation pearl.
A subgroup analysis from Capitello-291 suggests patients treated with capivasertib in the first-line setting experienced less diarrhea and rash than those in later lines. This aligns with a broader trend where heavily pre-treated patients exhibit poorer drug tolerance. This finding supports considering potent targeted agents earlier in the treatment sequence to potentially improve tolerability and outcomes.
The HORIZON-GEA-01 trial for zanidatumab in gastric cancer mandated prophylactic loperamide (4mg BID) for all patients. This was necessary to manage the high rates of diarrhea (up to 80% of patients), a significant GI toxicity associated with the drug's mechanism of action.
The HORIZON-GEA-01 trial's control arm used a standard of care (trastuzumab + chemo) that was superseded in the US by the addition of pembrolizumab during the trial. This design was appropriate at launch but creates a slight disconnect with current US practice, requiring clinicians to interpret results in a new context.
New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.
The zanidatamab triplet regimen causes severe diarrhea in 25% of patients. Management requires mandatory prophylactic loperamide for the first seven days. Diarrhea onset often coincides with the end of prophylaxis (day 7-8), highlighting the need for proactive communication and potential continuation of loperamide to maintain patients on therapy.
In a phase 2 trial, the combination of zanidatumab and FOLFOX achieved a remarkable 95% response rate after two key modifications were made: adding prophylactic loperamide and dropping the 5-FU bolus. This suggests the bolus adds toxicity without clear benefit in this specific, potent combination.
To manage the significant diarrhea associated with the new drug zanidatumab, a proactive approach is critical. The successful HORIZON-GEA trial protocol included mandatory loperamide twice daily for the first seven days of cycle one, a strategy which effectively managed toxicity without leading to treatment discontinuation.
The TRAIL trial found starting abemaciclib at a low dose (50mg) and escalating every two weeks drastically improves tolerability. This approach reduced Grade 3 diarrhea from 7.8% in the pivotal trial to just 3.3% and lowered early discontinuation rates, allowing more patients to reach the full therapeutic dose and stay on treatment.
Diarrhea from the HER2-directed antibody zanidatumab is a common side effect, but it's most frequent and manageable in the first two cycles. Clinicians should proactively prescribe loperamide and educate patients, as the issue often resolves and rarely leads to treatment discontinuation.
